Literature DB >> 15902485

Cytoplasmic expression of c-erbB2 in non-small cell lung cancers.

Chun-Mei Cheng1, Koichi Tsuneyama, Kazuhiro Matsui, Hiroyuki Takahashi, Shin Ishizawa, Yasuo Takano.   

Abstract

The aim of this study was to investigate the expression of c-erbB2 in non-small cell lung cancers (NSCLCs) with attention both to membranous and cytoplasmic reaction, and to try to elucidate the meaning of cytoplasmic expression of c-erbB2 in NSCLCs. Immunohistochemical c-erbB2 expression and related clinico-pathological features were examined in 312 surgically resected patient tissues of NSCLCs, including 175 cases of adenocarcinoma and 137 cases of squamous cell carcinoma. Immunostaining of inner- and ecto-domain of c-erbB2, mRNA expression and the quantitation of soluble c-erbB2 in cultured media were performed in five NSCLC cell lines. Cytoplasmic expression of c-erbB2 was observed more frequently than membranous, both in patient tissues and cell lines. Neither membranous nor cytoplasmic expression of c-erbB2 was significantly correlated with short outcome in NSCLCs. Membranous c-erbB2 was expressed by both inner and ecto-domain, while cytoplasmic c-erbB2 was expressed by either or both inner and ecto-domain. c-erbB2 mRNA was produced in most cell lines; however, the soluble form was only detectable in a cell line that only presented a membranous c-erbB2. In conclusion, cytoplasmic c-erbB2 of NSCLCs was not a full-length protein only expressed in cellular membrane, but reflected degenerated c-erbB2 fragments with less functional ability.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15902485     DOI: 10.1007/s00428-005-1258-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  22 in total

Review 1.  CHIP: a quality-control E3 ligase collaborating with molecular chaperones.

Authors:  Shigeo Murata; Tomoki Chiba; Keiji Tanaka
Journal:  Int J Biochem Cell Biol       Date:  2003-05       Impact factor: 5.085

2.  Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital.

Authors:  Tokimasa Kumada; Koichi Tsuneyama; Hideki Hatta; Shin Ishizawa; Yasuo Takano
Journal:  Mod Pathol       Date:  2004-09       Impact factor: 7.842

3.  Expression of biomarkers (p53, transforming growth factor alpha, epidermal growth factor receptor, c-erbB-2/neu and the proliferative cell nuclear antigen) in oropharyngeal squamous cell carcinomas.

Authors:  S O Ibrahim; J R Lillehaug; A C Johannessen; P G Liavaag; R Nilsen; E N Vasstrand
Journal:  Oral Oncol       Date:  1999-05       Impact factor: 5.337

4.  Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2.

Authors:  L N Klapper; H Waterman; M Sela; Y Yarden
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

5.  HER2/neu expression in malignant lung tumors.

Authors:  Fred R Hirsch; Wilbur A Franklin; Robert Veve; Marileila Varella-Garcia; Paul A Bunn
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

6.  Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein.

Authors:  J T Wu; M E Astill; S D Gagon; L Bryson
Journal:  J Clin Lab Anal       Date:  1995       Impact factor: 2.352

Review 7.  C-erbB2 oncoprotein and its soluble ectodomain: a new potential tumor marker for prognosis early detection and monitoring patients undergoing Herceptin treatment.

Authors:  James T Wu
Journal:  Clin Chim Acta       Date:  2002-08       Impact factor: 3.786

8.  C-erbB-2 oncoprotein expression in operable non-small cell lung cancer.

Authors:  A Giatromanolaki; V Gorgoulis; R Chetty; M I Koukourakis; R Whitehouse; C Kittas; M Veslemes; K C Gatter; I Iordanoglou
Journal:  Anticancer Res       Date:  1996 Mar-Apr       Impact factor: 2.480

9.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

Authors:  J Baselga; L Norton; J Albanell; Y M Kim; J Mendelsohn
Journal:  Cancer Res       Date:  1998-07-01       Impact factor: 12.701

10.  Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas.

Authors:  F R Hirsch; M Varella-Garcia; W A Franklin; R Veve; L Chen; B Helfrich; C Zeng; A Baron; P A Bunn
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

View more
  2 in total

1.  Overexpression of c-erbB-2 and loss of p16 have molecular diagnostic relevance but no prognostic value in lung cancer.

Authors:  Xiao-li Feng; Ling Li; Yan-ning Gao; Jian-jun Zhang; Ting Xiao; Jian-ming Ying; Ji-dong Gao; Yun-tian Sun; Shu-jun Cheng
Journal:  Med Oncol       Date:  2010-03-17       Impact factor: 3.064

2.  Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer.

Authors:  Jie Liu; Angela Ahiekpor; Li Li; Xianxing Li; Patrick Arbuthnot; Michael Kew; Mark A Feitelson
Journal:  Int J Cancer       Date:  2009-10-15       Impact factor: 7.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.